Literature DB >> 25924698

The efficacy of radio-frequency ablation for metastatic lung or liver tumors of male germ cell tumors as an alternative minimally invasive therapy after salvage chemotherapy.

Yoshio Naya1, Terukazu Nakamura2, Masakatsu Oishi2, Takashi Ueda2, Hiroyuki Nakanishi2, Yasuyuki Naitoh2, Fumiya Hongo2, Kazumi Kamoi2, Koji Okihara2, Osamu Tanaka3, Takuji Yamagami3, Kei Yamada3, Tsuneharu Miki2.   

Abstract

BACKGROUND: The aim of this study was to assess the efficacy of radio-frequency ablation (RFA) for metastatic lung or liver tumors of germ cell tumors (GCTs) after chemotherapy.
METHODS: RFA with computed tomography guidance and monitoring was performed in 24 patients with 48 metastatic lung or liver tumors of GCTs. Group A consisted of 9 patients with tumor marker normalization after salvage chemotherapy and group B consisted of 15 patients without tumor marker normalization in spite ofintensive treatment.
RESULTS: Out of 48 tumors, 41 tumors in 21 patients were evaluated for the efficacy of the RFA treatment. Of the 41 tumors, successful ablation was achieved in 34 (82.9 %). The patients in group A had significantly better survival than the patients in group B (p = 0.0003). In group A, all 9 patients are still alive with no evidence of disease (NED). Patients with a solitary tumor had significantly better survival than those with multiple tumors (p = 0.0247). In group B, 2 patients are alive with NED, 1 patient is alive with disease, and the remaining 12 patients have died a tumor-related death. Three cases of pneumothorax requiring intubation were observed.
CONCLUSIONS: RFA is less invasive than surgery and is an effective treatment option for curative and palliative therapy as an alternative to invasive salvage surgery for post-chemotherapeutic metastatic lung or liver lesions from GCT.

Entities:  

Keywords:  Germ cell tumor; Lung or liver metastases; Radio-frequency ablation

Mesh:

Substances:

Year:  2015        PMID: 25924698     DOI: 10.1007/s10147-015-0824-5

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  14 in total

1.  Simultaneous retroperitoneal, thoracic, and cervical resection of postchemotherapy residual masses in patients with metastatic nonseminomatous germ cell tumors of the testis.

Authors:  P C Brenner; H W Herr; M J Morse; J Sheinfeld; A Aprikian; G J Bosl; R J Motzer; D F Bajorin; S Schantz; W R Fair; M Burt
Journal:  J Clin Oncol       Date:  1996-06       Impact factor: 44.544

2.  Comparison of histological results from the resection of residual masses at different sites after chemotherapy for metastatic non-seminomatous germ cell tumours.

Authors:  J T Hartmann; M Candelaria; M A Kuczyk; H J Schmoll; C Bokemeyer
Journal:  Eur J Cancer       Date:  1997-05       Impact factor: 9.162

3.  Outcome analysis for patients with elevated serum tumor markers at postchemotherapy retroperitoneal lymph node dissection.

Authors:  Stephen D W Beck; Richard S Foster; Richard Bihrle; Lawrence H Einhorn; John P Donohue
Journal:  J Clin Oncol       Date:  2005-09-01       Impact factor: 44.544

4.  Radio-frequency ablation of renal cell carcinoma in patients who were at significant risk.

Authors:  Osamu Ukimura; Akihiro Kawauchi; Akira Fujito; Yoichi Mizutani; Koji Okihara; Kazuya Mikami; Jintetsu Soh; Terukazu Nakamura; Hiroyuki Nakanishi; So Ushijima; Tsuneharu Miki
Journal:  Int J Urol       Date:  2004-12       Impact factor: 3.369

5.  Radiofrequency ablation of unresectable primary and metastatic hepatic malignancies: results in 123 patients.

Authors:  S A Curley; F Izzo; P Delrio; L M Ellis; J Granchi; P Vallone; F Fiore; S Pignata; B Daniele; F Cremona
Journal:  Ann Surg       Date:  1999-07       Impact factor: 12.969

6.  Radiofrequency ablation of 231 unresectable hepatic tumors: indications, limitations, and complications.

Authors:  T F Wood; D M Rose; M Chung; D P Allegra; L J Foshag; A J Bilchik
Journal:  Ann Surg Oncol       Date:  2000-09       Impact factor: 5.344

7.  Determinants of local progression after computed tomography-guided percutaneous radiofrequency ablation for unresectable lung tumors: 9-year experience in a single institution.

Authors:  Tomohisa Okuma; Toshiyuki Matsuoka; Akira Yamamoto; Yoshimasa Oyama; Shinichi Hamamoto; Masami Toyoshima; Kenji Nakamura; Yukio Miki
Journal:  Cardiovasc Intervent Radiol       Date:  2009-12-05       Impact factor: 2.740

8.  Radiofrequency ablation for renal tumors: our experience.

Authors:  Kenji Hiraoka; Akihiro Kawauchi; Terukazu Nakamura; Jintetsu Soh; Kazuya Mikami; Tsuneharu Miki
Journal:  Int J Urol       Date:  2009-09-03       Impact factor: 3.369

9.  Pulmonary radiofrequency ablation--an international study survey.

Authors:  Karin Steinke; Patrick E Sewell; Damien Dupuy; Riccardo Lencioni; Thomas Helmberger; Stephen T Kee; Augustinus L Jacob; Derek W Glenn; Julie King; David L Morris
Journal:  Anticancer Res       Date:  2004 Jan-Feb       Impact factor: 2.480

10.  Surgical treatment of liver metastases by radiofrequency ablation, resection, or in combination.

Authors:  S Evrard; Y Becouarn; M Fonck; R Brunet; S Mathoulin-Pelissier; V Picot
Journal:  Eur J Surg Oncol       Date:  2004-05       Impact factor: 4.424

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.